Physician profile
James K Ensor
NPI 1205811247
$10,314.74
in general payments reported to CMS, 2019-2025
46 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,661 · 2020: $1,331 · 2021: $1,821 · 2022: $1,179 · 2023: $1,953 · 2024: $1,318 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,323.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,485.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,079.64 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals Lp | $884.30 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $786.70 | 2019-2025 | Verquvo, Belsomra, Lagevrio |
| Novartis Pharmaceuticals Corporation | $645.98 | 2019-2025 | |
| Lilly USA, LLC | $573.90 | 2019-2024 | Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $485.14 | 2019-2023 | Cycloset, Trulance, Xifaxan |
| Abbvie INC. | $458.88 | 2020-2025 | |
| Genzyme Corporation | $342.14 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $309.99 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $281.67 | 2019-2025 | Seglentis, Zoryve |
| Otsuka America Pharmaceutical, INC. | $266.87 | 2023-2024 | Nuedexta, Rexulti |
| Allergan, INC. | $252.68 | 2019-2021 | |
| C2n Diagnostics, LLC | $244.49 | 2025 | Precivityad2 |
| Evoke Pharma, INC. | $179.36 | 2020-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ensor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.